Get the Stockscreener App
0.4478
1.56%
-0.0071
Cognition Therapeutics Inc stock is traded at $0.4478, with a volume of 500.06K.
It is down -1.56% in the last 24 hours and down -32.76% over the past month.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.
See More
Previous Close:
$0.4549
Open:
$0.449
24h Volume:
500.06K
Relative Volume:
0.06
Market Cap:
$18.73M
Revenue:
-
Net Income/Loss:
$-22.83M
P/E Ratio:
-0.5668
EPS:
-0.79
Net Cash Flow:
$-20.87M
1W Performance:
-20.14%
1M Performance:
-32.76%
6M Performance:
-29.37%
1Y Performance:
-77.61%
1-Day Range:
$0.4387
$0.4735
1-Week Range:
$0.4387
$0.615
52-Week Range:
$0.34
$2.95
Cognition Therapeutics Inc Stock (CGTX) Company Profile
Name
Cognition Therapeutics Inc
Sector
Industry
Phone
412-481-2210
Address
2403 SIDNEY STREET, PITTSBURGH
Compare CGTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CGTX
Cognition Therapeutics Inc
|
0.4483 | 18.73M | 0 | -22.83M | -20.87M | -0.79 |
|
VRTX
Vertex Pharmaceuticals Inc
|
490.11 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
688.45 | 75.07B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
632.13 | 37.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
242.19 | 31.79B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
112.67 | 27.34B | 3.30B | -501.07M | 1.03B | -2.1146 |
Cognition Therapeutics Inc Stock (CGTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-19-24 | Upgrade | B. Riley Securities | Neutral → Buy |
| Jul-30-24 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Nov-03-21 | Initiated | B. Riley Securities | Buy |
| Nov-03-21 | Initiated | Oppenheimer | Outperform |
Cognition Therapeutics Inc Stock (CGTX) Latest News
Chardan Capital Reaffirms Buy Rating for Cognition Therapeutics (NASDAQ:CGTX) - Defense World
Cognition Therapeutics Publishes Research Supporting the Potential of Zervimesine in Dry AMD - The Bakersfield Californian
Can Cognition's Zervimesine Tackle Dry AMD? New Research Reveals Promising Cellular Rescue - StockTitan
Cognition Therapeutics Reports Positive Futility Analysis Of Zervimesine In Geographic Atrophy - Nasdaq
Zervimesine shows promise in Phase 2 trial for dry AMD By Investing.com - Investing.com South Africa
Zervimesine shows promise in Phase 2 trial for dry AMD - Investing.com
Cognition Therapeutics Successfully Passes Pre-defined - GlobeNewswire
Cognition Therapeutics Successfully Passes Pre-defined Futility Analysis of Phase 2 Study of ... - The Bakersfield Californian
Can This Small Biotech's Drug Tackle Both Eye Disease AND Alzheimer's? Phase 2 Data Says Yes - StockTitan
Cognition Therapeutics, Inc. to Co-Host Precision Medicine Workshop at Neuroimmunology Drug Development Summit - Nasdaq
Cognition Therapeutics’ VP of Research Co-hosting Precision - GlobeNewswire
Can This Biomarker Strategy Revolutionize Alzheimer's Treatment? Cognition's 95% Improvement Data - StockTitan
Cognition Therapeutics Announces Publication of Commercial - GlobeNewswire
Cognition Therapeutics develops new drug manufacturing process By Investing.com - Investing.com Nigeria
Cognition Therapeutics develops new drug manufacturing process - Investing.com India
Cognition Therapeutics Announces Publication of Commercial Manufacturing Process for Lead ... - The Bakersfield Californian
Inside Cognition's Game-Changing Manufacturing Process: Will This Transform Alzheimer's Drug Production? - StockTitan
37,108 Shares in Cognition Therapeutics, Inc. (NASDAQ:CGTX) Acquired by SG Americas Securities LLC - Defense World
Cognition Therapeutics, Inc. (NASDAQ:CGTX) Receives Average Recommendation of “Buy” from Brokerages - Defense World
BIO CEO 2025: Cognition CEO debates policy while advancing CT-1812 - BioWorld Online
B. Riley Cuts Earnings Estimates for Cognition Therapeutics - Defense World
Investors in cash trouble should check out Cognition Therapeutics Inc (CGTX) - SETE News
B. Riley Adjusts Cognition Therapeutics Price Target to $2 From $1.50, Maintains Buy Rating - Marketscreener.com
Cognition Therapeutics Presents Phase 2 Results For Drug To Fight DLB At International Conference - Nasdaq
Cognition Therapeutics Inc (CGTX) receives a Buy rating from B. Riley Securities - Knox Daily
What technical indicators reveal about CGTX stock - US Post News
Director Makes Bold Move with Major Stock Purchase in Cognition Therapeutics - TipRanks
Can Cognition Therapeutics Inc Bounce Back? 52-Week Performance and Analyst Predictions - The InvestChronicle
Is Now The Time To Buy Cognition Therapeutics Inc (NASDAQ: CGTX) Stock? - Stocks Register
Cognition Therapeutics, Inc. (NASDAQ:CGTX) Short Interest Update - Defense World
A Data-Based Look At Cognition Therapeutics Inc (CGTX) - Stocks Register
Cognition’s Positive Phase 2 ‘SHIMMER’ Study of Zervimesine - GlobeNewswire
CGTXCOGNITION THERAPEUTICS INC Latest Stock News & Market Updates - StockTitan
Cognition Therapeutics Reports Positive Topline Results of Zervimesine in SHIMMER Study for Dementia with Lewy Bodies - Nasdaq
Cognition’s Positive Phase 2 ‘SHIMMER’ Study of Zervimesine (CT1812) in Dementia with Lewy - The Bakersfield Californian
New Dementia Drug Achieves Remarkable 91% Reduction in Cognitive FluctuationsPhase 2 Results Revealed - StockTitan
Brokers Issue Forecasts for CGTX FY2024 Earnings - Defense World
Lewy Body Dementia Market Deep Research Report with Forecast - openPR
Cognition Therapeutics (NASDAQ:CGTX) Raised to “Strong-Buy” at Brookline Capital Management - Defense World
70+ Key Companies Advancing in Dry Age-Related Macular Degeneration Clinical Trial Therapeutic Space | DelveInsight - The Malaysian Reserve
Cognition Therapeutics, Inc. (NASDAQ:CGTX) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World
Alzheimer's Disease Clinical and Non-Clinical Studies, Key - openPR
**Cognition Therapeutics (NASDAQ:CGTX) Prepares to Advance Treatment Efforts** ** - Defense World
Dry Age Macular Degeneration Pipeline Insights 2024: Therapies, Clinical Trials, Therapies and Key Companies involved by DelveInsight |Janssen R&D, Belite Bio, Katairo, Cognition Therapeutics - Barchart
Dry Age Macular Degeneration Pipeline Insights 2024: - openPR
Cognition Therapeutics Shows Promising Phase 2 Study Results - TipRanks
Cognition Therapeutics Is Targeting A Critical Form Of Dementia - Nasdaq
Cognition Therapeutics CEO Participating in Longwood and Sachs Conferences - The Manila Times
Cognition Therapeutics Advances DLB Treatment After Positive Phase 2 Results, CEO to Present at JPM Week - StockTitan
Cognition Therapeutics (NASDAQ:CGTX) versus Editas Medicine (NASDAQ:EDIT) Head-To-Head Contrast - Defense World
Cognition Therapeutics, Inc. (NASDAQ:CGTX) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World
Cognition Therapeutics Inc Stock (CGTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.34%
1.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):